




Amendments to the Specification

Please replace paragraph [0022] with the following amended paragraph:


[0022] The present invention relates to a method for treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of: (1) a compound having the formula




where Q is a group of the formula




R and R¹ are each independently C₁-C₄-alkyl, R₁ is thienyl, phenyl, cyclopentyl or cyclohexyl, and X⁻ is a physiologically acceptable anion; (2) a compound having the formula




where X^- is a physiologically acceptable ion; (3) a compound having the formula




where X^- is a physiologically acceptable ion; (4) a compound having the formula




where R_1 is 2-thienyl or cyclopentyl, and A is 3 α -(6,7-dehydro)-tropanyl methobromide, 3 β -tropanyl methobromide, or 3 α -(N-isopropyl)-nortropanyl methobromide; (5) a compound having the formula





where R is an optionally halo- or hydroxyl-substituted C_{1-4} alkyl group, R^1 is a C_{1-4} -alkyl group, or R and R^1 together form a C_{4-6} -alkylene group, X^- is a physiologically acceptable anion, and R_1 is H, OH, CH_3 , CH_2OH , C_{1-4} alkyl or C_{1-4} -alkoxy; (6) a compound having the formula




where R is an optionally halo- or hydroxy-substituted C_{1-4} -alkyl group, R^1 is a C_{1-4} -alkyl group, or R and R^1 together form a C_{4-6} - alkylene group, X^- is a physiologically acceptable anion and R_1 is H, OH, CH_3 , CH_2OH , C_{1-4} -alkyl or C_{1-4} -alkoxy; (7) a compound having the formula



(8) a compound having the formula




and (9) a compound having the formula





where X^- is a physiologically acceptable anion.

Please replace paragraph [0024] with the following amended paragraph:

[0024] The present invention relates to a method for treating bladder disease in a subject. This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of: a compound having the formula





where Q is a group of the formula



R and R¹ are each independently C₁-C₄-alkyl, R₁ is thienyl, phenyl, cyclopentyl or cyclohexyl, and X⁻ is a physiologically acceptable anion. In this aspect and all aspects of the present invention, R may be, without limitation, CH₃, C₂H₅, n-C₃H₇, or i-C₃H₇; R¹ may be, without limitation, CH₃, and X⁻ is meant to include, without limitation, bromide (Br⁻) and CH₃SO₃.


Please replace paragraph [0031] with the following amended paragraph:

[0031] In another aspect of the present invention, treatment of a bladder disease involves administering to a subject a compound having the formula



Please replace paragraph [0032] with the following amended paragraph:

[0032] In another aspect of the present invention, treatment of a bladder disease involves administering to a subject a compound having the formula



where X^- is a physiologically acceptable ion as described herein above.